ArticleJournal of Cancer2017
Identification of Nucleobindin-2 as a Potential Biomarker for Breast Cancer Metastasis Using iTRAQ-based Quantitative Proteomic Analysis.
Article in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Dysregulation of adipokines in the serum of breast cancer patients - role in pathogenesis and potential clinical application (preliminary studies).Frontiers in immunology · 2026Article
- Proteomics in Diagnostic Evaluation and Treatment of Breast Cancer: A Scoping Review.Journal of personalized medicine · 2025Review
- Deciphering Cancer Complexity: Integrative Proteogenomics and Proteomics Approaches for Biomarker Discovery.Methods in molecular biology (Clifton, N.J.) · 2025Review
- NUCB2/Nesfatin-1 drives breast cancer metastasis through the up-regulation of cholesterol synthesis via the mTORC1 pathway.Journal of translational medicine · 2023Article
- Does one plus one always equal two? Structural differences between nesfatin-1, -2, and nesfatin-1/2.Cell communication and signaling : CCS · 2022Article
- Expression of NUCB2/NESF-1 in Breast Cancer Cells.International journal of molecular sciences · 2022Article
- NUCB2: roles in physiology and pathology.Journal of physiology and biochemistry · 2022Review
- Proteome analysis of urinary biomarkers in a cigarette smoke-induced COPD rat model.Respiratory research · 2022Article
- iTRAQ proteomics of sentinel lymph nodes for identification of extracellular matrix proteins to flag metastasis in early breast cancer.Scientific reports · 2022Article
- Nucleobindin-2/Nesfatin-1-A New Cancer Related Molecule?International journal of molecular sciences · 2021Review
- Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment.NPJ breast cancer · 2021Article
- Proteomics and its applications in breast cancer.American journal of cancer research · 2021Review
- Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers.Theranostics · 2020Observational
- Prognostic value of biomarkers EpCAM and αB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis.BMC cancer · 2019Article
- Dynamic urinary proteomic analysis in a Walker 256 intracerebral tumor model.Cancer medicine · 2019Article
- XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients.Frontiers in oncology · 2019Article
- High expression of NUCB2 promotes papillary thyroid cancer cells proliferation and invasion.OncoTargets and therapy · 2019Article
- Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma.Journal of Cancer · 2019Article
- Protein S100-A8: A potential metastasis-associated protein for breast cancer determined via iTRAQ quantitative proteomic and clinicopathological analysis.Oncology letters · 2018Article
- Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer.Disease markers · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis is a lethal step in the progression of breast cancer. None of the metastasis-associated biomarkers identified up to now has a definite prognostic value in breast cancer patients. This study was designed to identify biomarkers for breast cancer metastasis and predictors of the prognosis of breast cancer patients. The differentially expressed proteins between 23 paired primary breast tumor and metastatic lymph nodes were identified by quantitative iTRAQ proteomic analysis. Immunohistochemistry was applied to locate and assess the expression of NUCB2 in paired primary breast tumor and metastatic lymph node tissues (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.